Glaukos (GKOS)
NYSE:GKOS
Want to see GKOS full AI Analyst Report?
Top Page
Glaukos
(NYSE:GKOS)
Select Model
Select Model
Rating:62Neutral
Price Target:
$152.00
▲(21.80% Upside)
Action:ReiteratedDate:05/01/26
The score is driven by strong technical momentum and a notably positive earnings update (record results and raised guidance with expanding gross margins). This is tempered by weak underlying financial performance due to ongoing losses and cash burn, and limited valuation support given the negative P/E and no dividend.
Positive Factors
Revenue Growth & Raised Guidance
Sustained, high-teens to mid-double-digit top-line growth and a management-initiated guidance raise reflect durable commercial traction across franchises. Strong organic revenue expansion improves scale economics, funds R&D and commercialization, and underpins multi-quarter strategic execution.
Negative Factors
Negative Operating and Free Cash Flow
Persistent negative operating and free cash flow means the business remains cash‑consumptive despite improvement. Ongoing reliance on external liquidity raises financing and dilution risk, constrains optionality for opportunistic investments, and makes the firm vulnerable to execution or market access setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Raised Guidance
Sustained, high-teens to mid-double-digit top-line growth and a management-initiated guidance raise reflect durable commercial traction across franchises. Strong organic revenue expansion improves scale economics, funds R&D and commercialization, and underpins multi-quarter strategic execution.
Read all positive factors
Glaukos (GKOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.41B
Dividend YieldN/A
Average Volume (3M)692.11K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth36.30%
EPS Growth-42.48%
CountryUS
Employees995
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.18
Shares Outstanding58,527,220
10 Day Avg. Volume640,360
30 Day Avg. Volume692,113
Financial Highlights & Ratios
PEG Ratio-1.87
Price to Book (P/B)9.84
Price to Sales (P/S)12.73
P/FCF Ratio-119.57
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue12.41
Enterprise Value/Gross Profit15.59
Enterprise Value/Ebitda-43.11
Forecast
1Y Price Target
$141.20Price Target Upside13.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$613.29M
Glaukos Business Overview & Revenue Model
Company Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject ...
How the Company Makes Money
Glaukos makes money primarily by selling ophthalmic products to hospitals, ambulatory surgery centers, and eye-care providers through direct sales and distribution channels. Its largest revenue stream has historically been product revenue from its...
Glaukos Key Performance Indicators (KPIs)
Any
Revenue by Geography
Shows where Glaukos earns its sales across regions (U.S., EMEA, APAC), revealing which markets drive growth, where adoption of its ophthalmic implants and consumables is strongest, and how exposed the business is to currency, reimbursement, or regulatory risk. A heavy concentration in one region signals dependency, while faster growth overseas points to expansion opportunities and long-term upside.
Shows where Glaukos earns its sales across regions (U.S., EMEA, APAC), revealing which markets drive growth, where adoption of its ophthalmic implants and consumables is strongest, and how exposed the business is to currency, reimbursement, or regulatory risk. A heavy concentration in one region signals dependency, while faster growth overseas points to expansion opportunities and long-term upside.
Data provided by:
The Fly
The FlyGlaukos Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call highlighted strong commercial execution and meaningful growth: record Q1 revenue (+41% reported), raised guidance, robust U.S. glaucoma performance driven by iDose TR, encouraging early commercial and access milestones for Epioxa (including CMS J-code and >100M covered lives), improved gross margin, and a deep clinical pipeline with clear regulatory timelines. Near-term challenges include payer adoption frictions for Epioxa during the miscellaneous J-code period, expected quarter-to-quarter volatility in Corneal Health during the Photrexa-to-Epioxa transition (notably a Q2 dip), potential international competitive and currency headwinds, modestly higher operating expenses to fund launches, and residual policy/LCD risk for interventional glaucoma. Overall, the positive commercial momentum, material guidance raise, margin accretion, and pipeline progress materially outweigh the near-term operational and access headwinds.Positive Updates
Record Consolidated Net Sales and Raised Guidance
Q1 consolidated net sales of $150.6M, up 41% reported and 39% constant currency year-over-year. Raised full-year 2026 net sales guidance to $620M–$635M (from $600M–$620M).
Negative Updates
Epioxa Early Adoption Hurdles and Transition Friction
Initial adoption is gated by payer adoption and prior-authorization workflows. Early commercialization uses a miscellaneous J-code leading to slower, claim-by-claim adjudication until product-specific J-code takes effect July 1, 2026. Company expects measured adoption in the near-term and some elongated patient access cycles.
Read all updates
Q1-2026 Updates
Positive
Negative
Record Consolidated Net Sales and Raised Guidance
Q1 consolidated net sales of $150.6M, up 41% reported and 39% constant currency year-over-year. Raised full-year 2026 net sales guidance to $620M–$635M (from $600M–$620M).
Read all positive updates
Company Guidance
Glaukos raised 2026 net sales guidance to $620.0–$635.0 million (from $600.0–$620.0M) after reporting record Q1 consolidated net sales of $150.6M (up 41% reported, 39% constant currency); franchise detail included U.S. glaucoma net sales of $93.5M (up 58% YoY) with iDose TR contributing roughly $54M, international glaucoma $35.8M (up 23% reported, 16% constant currency) with management expecting high‑single‑digit growth for the remainder of 2026 and low‑double‑digit for the full year, and Corneal Health $21.3M (up 15%) including Fetrexan and very early Epioxa sales of $17.7M and an expected high‑single‑digit full‑year growth with quarter-to-quarter volatility (a Q2 dip anticipated during the Photrexa→Epioxa transition); corporate gross margin was 84% in Q1 with guidance of ~84–86% for 2026, operating expenses expected to rise modestly (still in the “high‑teens” range year‑over‑year) as the company invests in commercialization while targeting operating‑leverage and cash‑flow breakeven, and Epioxa launch metrics include ~65% U.S. population coverage today (target ~95%), >100M commercial lives with pathways established, and a CMS product‑specific J‑code (J2789) effective July 1, 2026.Glaukos Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 551.35M | 507.44M | 383.48M | 314.71M | 282.86M | 294.01M |
| Gross Profit | 439.11M | 282.76M | 289.45M | 239.14M | 213.88M | 227.38M |
| EBITDA | -158.75M | -150.31M | -95.64M | -82.12M | -48.76M | -1.47M |
| Net Income | -189.33M | -187.69M | -146.37M | -134.66M | -99.19M | -49.59M |
Balance Sheet | ||||||
| Total Assets | 893.33M | 893.49M | 974.76M | 940.41M | 1.07B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 276.69M | 278.76M | 318.92M | 295.43M | 352.69M | 414.05M |
| Total Debt | 103.06M | 139.64M | 105.87M | 383.74M | 382.91M | 383.38M |
| Total Liabilities | 222.40M | 237.33M | 207.82M | 478.65M | 544.16M | 541.68M |
| Stockholders Equity | 670.93M | 656.15M | 766.93M | 461.77M | 530.00M | 587.15M |
Cash Flow | ||||||
| Free Cash Flow | -18.48M | -54.01M | -67.62M | -78.01M | -63.35M | -23.08M |
| Operating Cash Flow | -8.79M | -46.34M | -61.32M | -57.76M | -33.08M | 24.71M |
| Investing Cash Flow | -30.16M | -77.61M | 47.83M | 14.10M | 44.78M | -58.23M |
| Financing Cash Flow | 25.70M | 11.89M | 91.54M | 15.04M | 6.25M | 39.26M |
Glaukos Technical Analysis
Positive
124.79
Price Trends
111.96
Positive
112.53
Positive
100.86
Positive
Market Momentum
3.63
Negative
67.46
Neutral
85.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GKOS, the sentiment is Positive. The current price of 124.79 is above the 20-day moving average (MA) of 113.27, above the 50-day MA of 111.96, and above the 200-day MA of 100.86, indicating a bullish trend. The MACD of 3.63 indicates Negative momentum. The RSI at 67.46 is Neutral, neither overbought nor oversold. The STOCH value of 85.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GKOS.
Glaukos Risk Analysis
Glaukos disclosed 25 risk factors in its most recent earnings report. Glaukos reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Glaukos Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.48B | 25.04 | 17.36% | ― | 19.50% | 15.27% | |
68 Neutral | $3.29B | -13.83 | -21.49% | ― | 11.08% | -485.09% | |
62 Neutral | $8.41B | -34.40 | -26.46% | ― | 36.30% | -42.48% | |
62 Neutral | $3.02B | 26.50 | 6.05% | ― | 6.49% | -18.21% | |
58 Neutral | $4.24B | -127.47 | -38.33% | ― | 26.24% | 61.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $1.34B | -7.22 | -141.98% | ― | 7.93% | -108.60% |
* Healthcare Sector Average
GKOS
Glaukos
140.22
52.61
60.05%
ITGR
Integer Holdings
84.03
-41.63
-33.13%
UFPT
Ufp Technologies
194.07
-8.14
-4.03%
TNDM
Tandem Diabetes Care
19.42
-2.06
-9.59%
LIVN
LivaNova
61.00
24.22
65.85%
IRTC
Irhythm Technologies
120.80
-10.32
-7.87%
Glaukos Corporate Events
Business Operations and StrategyFinancial Disclosures
Glaukos Boosts Outlook After Strong First-Quarter 2026 Results
Positive
Apr 29, 2026
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology specialist in glaucoma, corneal and retinal therapies, reported strong first-quarter 2026 performance on April 29, 2026, driven by its micro-invasive glaucoma devices and new...
Business Operations and StrategyProduct-Related Announcements
Glaukos Highlights Interventional Ophthalmology Strategy in Investor Update
Positive
Mar 2, 2026
Glaukos Corporation released an investor presentation in March 2026 outlining its strategy to transform glaucoma and keratoconus care through interventional, dropless therapies and to build durable new markets in ophthalmology. The company emphasi...
Business Operations and StrategyFinancial Disclosures
Glaukos Reports Record Q4 Sales, Reaffirms 2026 Outlook
Positive
Feb 17, 2026
On February 17, 2026, Glaukos reported record fourth-quarter 2025 net sales of $143.1 million, up 36% year over year, driven by a 42% surge in glaucoma revenue and 53% growth in U.S. glaucoma sales, while full-year 2025 revenue climbed 32% to $507...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.